SCHEMBL319087

SCHEMBL319087

COC(=O)c1sc(-c2ccc(Oc3ccccc3)cc2)cc1N(CC(=O)N1CCOCC1)C(=O)C1CCC(C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2E1 P05181 1/20 0.54
▸ HTT P42858 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ CHRM3 P20309 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ HSD17B10 Q99714 2/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ PTPRA P18433 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ NR2E3 Q9Y5X4 1/20 0.36
▸ NCOR2 Q9Y618 1/20 0.36
▸ MMP2 P08253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL319086 1.00 CYP2E1 (0.54) CYP2E1HTTALDH1A1KDM4EMEN1
SCHEMBL319107 0.94 CYP2E1 (0.61) CYP2E1HTTALDH1A1KDM4EMEN1
SCHEMBL319108 0.94 CYP2E1 (0.61) CYP2E1HTTALDH1A1KDM4EMEN1
SCHEMBL320238 0.94 CYP2E1 (0.57) CYP2E1HTTALDH1A1KDM4ELMNA
SCHEMBL320239 0.94 CYP2E1 (0.57) CYP2E1HTTALDH1A1KDM4ELMNA
SCHEMBL319051 0.87 CYP2E1 (0.67) CYP2E1CHRM3HSD17B10PTGS2MAPT
SCHEMBL319050 0.87 CYP2E1 (0.67) CYP2E1CHRM3HSD17B10PTGS2MAPT
SCHEMBL318365 0.82 KDM4E (0.40) HTTALDH1A1KDM4ECHRM3HTR2C
SCHEMBL10265449 0.81 CYP2E1 (0.61) CYP2E1ALDH1A1MEN1SMN1; SMN2MAPT
SCHEMBL10265447 0.81 CYP2E1 (0.58) CYP2E1ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 — — US disclosed
EP-2585447-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2013-05-01 — — EP disclosed
WO-2012006055-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS SLC10A1, ACE, CEL CYP2E1 1027/4885HTT 1551/4885ALDH1A1 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback